The New Trends in Fibrinolysis symposium, sponsored by Boehinger Ingelheim, took place virtually on August 28th as part of the 2021 ESC Congress. Chaired by CVC Founding Director Dr. Paul Armstrong, the session sought to: Recognize the challenges in STEMI care, particularly in reducing ischaemic time and establishing STEMI networks. Apply given strategies to overcome […]
“We build too many walls and not enough bridges.” -Isaac Newton While the pandemic walled us in physically, the CVC continued to build virtual bridges to improve our understanding of cardiovascular disease. Accordingly, the theme of our 2020 CVC annual report is ‘Bridging the Gap‘ and it collates some of the key advances engineered in part […]
The CVC is proud to congratulate co-director Dr. Padma Kaul on her recent appointment as the Heart & Stroke Chair in Cardiovascular Research. As per the University of Alberta announcement, In her role as Heart & Stroke Chair in Cardiovascular Research, Dr. Kaul will be responsible for being a leader in the development of cardiovascular […]
Vericiguat is the first soluble guanylate cyclase stimulator approved to treat heart failure.
